Is ovarian cancer risk associated with a common variant in the promoter sequence of the mismatch repair gene MLH1?
The G>A nt-93 variant of the MLH1 gene is associated with an increased risk of invasive ovarian cancer.
These in vitro findings demonstrate that CBM can reduce the formation but not the activity of multinucleated osteoclasts. Our data further reveal that the formation of osteogenic cells from their progenitors is not reduced by the CBM. Overall, our results suggest that the beneficial effects of CBM during graft consolidation may involve their direct impact on osteoclastogenesis.